Piermont Capital Management’s Emergent Biosolutions EBS Stock Holding History

Piermont Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-35,594	Closed	-$1.12M	–	256
2016 Q3	$1.12M	Buy	35,594 +3,020	+9%	+$87.8K	0.27%	155
2016 Q2	$916K	Buy	32,574 +10,504	+48%	+$412K	0.24%	169
2016 Q1	$802K	Buy	22,070 +400	+2%	+$14.1K	0.26%	106
2015 Q4	$867K	Sell	21,670 -1,440	-6%	-$50.2K	0.28%	107
2015 Q3	$658K	Hold	23,110	–	–	0.21%	110
2015 Q2	$761K	Hold	23,110	–	–	0.23%	110
2015 Q1	$665K	Buy	23,110 +7,760	+51%	+$223K	0.2%	123
2014 Q4	$418K	Hold	15,350	–	–	0.15%	117
2014 Q3	$327K	Buy	+15,350	New	+$351K	0.13%	139
2014 Q2	–	Sell	-8,500	Closed	-$215K	–	156
2014 Q1	$215K	Buy	+8,500	New	+$215K	0.1%	118

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piermont Capital Management's EBS Position: Q4 2016 in Review

Piermont Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2016, closing a stake of 35,594 shares — an estimated $1.12M sold.

Piermont Capital Management first reported a position in EBS in Q1 2014 and held it in 10 quarters. The position peaked at $1.12M in Q3 2016. 208 funds tracked by Wall St. Rank hold EBS as of Q4 2016.

Piermont Capital Management reported no remaining Emergent Biosolutions position as of Q4 2016 after selling out during the quarter.
Piermont Capital Management sold 35,594 Emergent Biosolutions shares in Q4 2016, an estimated $1.12M.
Piermont Capital Management first reported a position in Emergent Biosolutions in Q1 2014 and held it in 10 quarters.
Piermont Capital Management's Emergent Biosolutions position peaked at $1.12M in Q3 2016.
208 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2016.

Based on Piermont Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.